Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Prostate Cancer

Free Subscription 27.04.2026 1 Acta Radiol 1 BJU Int 1 BMC Cancer 2 BMC Urol 1 Br J Radiol 1 Cancer Lett 1 Clin Cancer Res 1 Eur Radiol 2 Hum Pathol 2 Int J Cancer 4 Int J Radiat Oncol Biol Phys 2 Int J Urol 1 J Natl Cancer Inst 2 J Nucl Med 2 N Engl J Med 1 Proc Natl Acad Sci U S A 2 Prostate 1 Ther Adv Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Radiol

1. JAMBOR I, Merisaari H
   Short-term repeatability of monoexponential apparent diffusion coefficient in prostate cancer: dependence on b-value, tumor grade, lesion size, and lesion location.
   Acta Radiol. 2026 Apr 20:2841851261441869. doi: 10.1177/02841851261441869.
   PubMed         Abstract available
   
   

   
   BJU Int

2. BRUINS SLOT AS, Sweere V, Heetman JG, Hermsen R, et al
   Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.
   BJU Int. 2026 Apr 20. doi: 10.1111/bju.70293.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. SOLER-LOPEZ A, Gomez-Carmona CD, Gonzalez-Devesa D, Lopez-Plaza D, et al
   Standardized Program of Resistance Training for Prostate Cancer Patients Receiving Androgen Deprivation Therapy (SPoRT-PCa-ADT): study protocol for a randomized controlled trial.
   BMC Cancer. 2026 Apr 22. doi: 10.1186/s12885-026-15902.
   PubMed        
   
   

   
   BMC Urol

4. PARRY MG, Bailey AV, Belin TR, Elashoff D, et al
   Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer.
   BMC Urol. 2026 Apr 18. doi: 10.1186/s12894-026-02146.
   PubMed        
   
   
5. SULHAN H, Kalyenci B
   Additional predictive value of systemic inflammation indices beyond prostate specific antigen density for clinically significant prostate cancer.
   BMC Urol. 2026 Apr 18. doi: 10.1186/s12894-026-02156.
   PubMed        
   
   

   
   Br J Radiol

6. OZBILEN MH, Karaca E, Sagmak B, Kok YE, et al
   Prediction of Upgrading in Clinically Insignificant Prostate Cancer Patients Undergoing Radical Prostatectomy: The Value of Ga-68-PSMA PET/CT.
   Br J Radiol. 2026 Apr 17:tqag085. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Cancer Lett

7. JIANG Y, Cheng S, Zhang CY, Jin X, et al
   HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable driver of lineage plasticity across cancers.
   Cancer Lett. 2026;648:218465.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

8. MAKOVEC A, Gustafson AP, Gandhi N, Rampalli S, et al
   B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups.
   Clin Cancer Res. 2026 Apr 21. doi: 10.1158/1078-0432.CCR-26-0322.
   PubMed         Abstract available
   
   

   
   Eur Radiol

9. ABRAHAMSEN BS, Knudtsen IS, Tulipan AJ, Hernes E, et al
   Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer.
   Eur Radiol. 2026 Apr 23. doi: 10.1007/s00330-026-12496.
   PubMed         Abstract available
   
   

   
   Hum Pathol

10. LANIPEKUN OK, Wang Y, Miyamoto H
    Global vs. individual scoring when prostate needle cores from a single systematic biopsy site show Gleason score heterogeneity.
    Hum Pathol. 2026;171:106075.
    PubMed         Abstract available
    
    
11. WU DJ, Pacheco R, Chan E, Lowe AC, et al
    Prostatic adenocarcinoma identified on transurethral resection of bladder tumor: A clinicopathologic series of a diagnostically relevant potential pitfall.
    Hum Pathol. 2026;171:106059.
    PubMed         Abstract available
    
    

    
    Int J Cancer

12. HAN Z, Yi X, Tang Y, Li X, et al
    Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer.
    Int J Cancer. 2026 Apr 22. doi: 10.1002/ijc.70512.
    PubMed         Abstract available
    
    
13. BRENTNALL AR, Rebolj M, Sasieni P, Funston G, et al
    Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.
    Int J Cancer. 2026 Apr 22. doi: 10.1002/ijc.70492.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

14. SHERRY AD, Ludmir EB, Tang C
    Setting the TRAP for Oligoprogressive Prostate Cancer: The Impetus for Prospective Evidence.
    Int J Radiat Oncol Biol Phys. 2026;125:295-297.
    PubMed        
    
    
15. ZILLI T, Zaorsky NG, Maitre P, Desai N, et al
    Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?
    Int J Radiat Oncol Biol Phys. 2026;125:11-14.
    PubMed        
    
    
16. SINGH M, Katdare A, Ghosh S, Choudhury S, et al
    PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2026;125:203-213.
    PubMed         Abstract available
    
    
17. RATNAKUMARAN R, Sasitharan A, Khan A, Mayet H, et al
    Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study.
    Int J Radiat Oncol Biol Phys. 2026;125:250-256.
    PubMed         Abstract available
    
    

    
    Int J Urol

18. YE D, Saad M, Lee JY, Jung W, et al
    Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE St
    Int J Urol. 2026;33:e70455.
    PubMed         Abstract available
    
    
19. NAKANISHI Y, Okumura G, Ikezoe E, Gozu S, et al
    Impact of Preoperative Diagnosis of Overactive Bladder and Intravesical Prostatic Protrusion on Postoperative Overactive Bladder Symptom Improvement Following Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70470.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

20. CHEN KL, Craig TK, Blackford AL, Warren JL, et al
    Federal housing assistance, cancer care, and overall survival among older adults with prostate cancer.
    J Natl Cancer Inst. 2026 Apr 22:djag099. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

21. LING SW, Konijnenberg M, Segbers M, Hooijman E, et al
    Phase 1 Dose-Escalation Study of [(225)Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.
    J Nucl Med. 2026 Apr 22:jnumed.125.271880. doi: 10.2967/jnumed.125.271880.
    PubMed         Abstract available
    
    
22. KIRCHHOFF S, Erber B, Rauscher I, Sasse D, et al
    Prognostic Value of [(18)F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.
    J Nucl Med. 2026 Apr 22:jnumed.125.271488. doi: 10.2967/jnumed.125.271488.
    PubMed         Abstract available
    
    

    
    N Engl J Med

23. SHORE ND, Freedland SJ
    Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
    N Engl J Med. 2026;394:1661-1662.
    PubMed        
    
    
24. ZHANG X, Zhou M, Zhao P
    Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2026;394:1661.
    PubMed        
    
    

    
    Proc Natl Acad Sci U S A

25. LI J, Yang F, Zhang X, Xu L, et al
    Loss of UFL1 drives chromosome instability and tumorigenesis of prostate cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2523965123.
    PubMed         Abstract available
    
    

    
    Prostate

26. KIKILI CI, Kapar C, Yagmur FH, Arslan E, et al
    The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2026 Apr 22. doi: 10.1002/pros.70185.
    PubMed         Abstract available
    
    
27. YUKIHIRO K, Sekino Y, Goto K, Saito K, et al
    Impact of the Nadir Androgen Receptor Signaling Inhibitor-Derived Integrative Response Model in Real-World Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Prostate. 2026 Apr 22. doi: 10.1002/pros.70186.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

28. BAI X, Chen Y, Yuan L, Xu S, et al
    Diagnostic performance of apparent diffusion coefficients for prostate cancer in patients with PI-RADS 4-5 lesions: a retrospective analysis.
    Ther Adv Urol. 2026;18:17562872261442021.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum